Zai Lab Says China Renews 3 Medicines in 2025 National Reimbursement Drug List

MT Newswires Live

12/08

Zai Lab (ZLAB) said Sunday that China's National Healthcare Security Administration renewed Vyvgart, Nuzyra and Zejula in its 2025 National Reimbursement Drug List.

The company said Vyvgart was renewed for the treatment of certain adult patients with generalized myasthenia gravis, while Nuzyra was renewed for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Zejula was renewed for the maintenance treatment of platinum-sensitive, first-line and recurrent ovarian cancer adult patients.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2589588543"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589588543\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589588543?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 20:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589588543","market":"nz","top_or_hot":-1,"title":"Zai Lab Says China Renews 3 Medicines in 2025 National Reimbursement Drug List","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ZAILF\">Zai Lab</a> (ZLAB) said Sunday that China's <a href=\"https://laohu8.com/S/NHC\">National Healthcare</a> Security Administration renewed Vyvgart, Nuzyra and Zejula in its 2025 National Reimbursement Drug List.</p><p>The company said Vyvgart was renewed for the treatment of certain adult patients with generalized myasthenia gravis, while Nuzyra was renewed for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.</p><p>Zejula was renewed for the maintenance treatment of platinum-sensitive, first-line and recurrent ovarian cancer adult patients.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zai Lab Says China Renews 3 Medicines in 2025 National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZai Lab Says China Renews 3 Medicines in 2025 National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-08 20:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ZAILF\">Zai Lab</a> (ZLAB) said Sunday that China's <a href=\"https://laohu8.com/S/NHC\">National Healthcare</a> Security Administration renewed Vyvgart, Nuzyra and Zejula in its 2025 National Reimbursement Drug List.</p><p>The company said Vyvgart was renewed for the treatment of certain adult patients with generalized myasthenia gravis, while Nuzyra was renewed for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.</p><p>Zejula was renewed for the maintenance treatment of platinum-sensitive, first-line and recurrent ovarian cancer adult patients.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2589588543","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589588543","pubTimestamp":1765197202,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zai Lab  said Sunday that China's National Healthcare Security Administration renewed Vyvgart, Nuzyra and Zejula in its 2025 National Reimbursement Drug List.The company said Vyvgart was renewed for the treatment of certain adult patients with generalized myasthenia gravis, while Nuzyra was renewed for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.Zejula was renewed for the maintenance treatment of platinum-sensitive, first-line and recurrent ovarian cancer adult patients.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4548":"巴美列捷福持仓","BK4139":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4526":"热门中概股","ZLAB":"再鼎医药","NHLD":"National Holdings Corporation","BK4531":"中概回港概念","MDCO":"麦迪逊医药"},"translate_title":"再鼎医药称中国在2025年国家报销药品目录续签3种药品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCO":1.5,"ZLAB":1,"NHLD":1.5},"content_text":"Zai Lab (ZLAB) said Sunday that China's National Healthcare Security Administration renewed Vyvgart, Nuzyra and Zejula in its 2025 National Reimbursement Drug List.The company said Vyvgart was renewed for the treatment of certain adult patients with generalized myasthenia gravis, while Nuzyra was renewed for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.Zejula was renewed for the maintenance treatment of platinum-sensitive, first-line and recurrent ovarian cancer adult patients.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}